Related Experiment Video
Updated: Jun 23, 2025
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
Zeolite and Neurodegenerative Diseases
Stefan Panaiotov1, Lyubka Tancheva2, Reni Kalfin2,3
1National Centre of Infectious and Parasitic Diseases, Yanko Sakazov Blvd. 26, 1504 Sofia, Bulgaria.
Molecules (Basel, Switzerland)
|June 19, 2024
Summary
Clinoptilolite zeolite shows promise for neurodegenerative diseases (NDs) by improving gut health and exhibiting detoxifying effects. This review explores its potential in treating Alzheimer
Area of Science:
- Mineralogy and Materials Science
- Neuroscience and Neurology
- Microbiology and Gut Health
Background:
- Neurodegenerative diseases (NDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), are progressive neuronal disorders linked to aging, with increasing prevalence and limited treatment options.
- Emerging research highlights a strong connection between intestinal health, the gut microbiome, and the pathogenesis of AD and PD, suggesting retrograde spread from the gut to the brain.
- Zeolites, particularly clinoptilolite, are microporous minerals with potential therapeutic applications due to their unique structural properties.
Purpose of the Study:
- To review the multifaceted benefits of clinoptilolite and its activated forms on gut health and the gut microbiome.
- To discuss the detoxifying, antioxidative, immunostimulatory, and anti-inflammatory properties of clinoptilolite relevant to ND treatment.
- To examine the direct impact of clinoptilolite on AD pathology and its potential use in PD management as biosensors and delivery systems.
Main Methods:
- Comprehensive literature review of existing studies on clinoptilolite, gut health, and neurodegenerative diseases.
- Analysis of in vitro and in vivo data concerning clinoptilolite's effects on AD pathology.
- Exploration of research on zeolites as biosensors and drug delivery systems for PD.
Main Results:
- Clinoptilolite demonstrates significant positive effects on gut health and modulation of the gut microbiome.
- The mineral exhibits potent detoxifying, antioxidative, immunostimulatory, and anti-inflammatory activities.
- Evidence suggests direct beneficial effects of clinoptilolite on AD pathology and potential applications in PD diagnostics and therapeutics.
Conclusions:
- Clinoptilolite and its activated forms represent a promising natural therapeutic agent for managing neurodegenerative diseases, particularly AD and PD.
- Its beneficial effects on the gut microbiome and its intrinsic detoxifying and anti-inflammatory properties are key to its therapeutic potential.
- Further research into clinoptilolite's direct impact on neurodegenerative pathways and its application in advanced delivery systems is warranted.
Related Concept Videos
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:15Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179